Related Experiment Video
Updated: Feb 6, 2026

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
Perspectives on IDH Mutation in Diffuse Gliomas
Yu-Ting Su1, Funita P Phan1, Jing Wu1
1Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, 20892, USA.
Abstract:
Isocitrate dehydrogenase (IDH) mutations are biomarkers to classify diffuse gliomas into biologically similar subgroups. Tremendous efforts have been made to understand the biology of IDH-mutant gliomas at the genetic, epigenetic, transcriptional, and protein levels. Preclinical models that recapitulate human tumor biology are crucial not only to our understanding of IDH mutations in gliomagenesis, but also in testing of novel therapeutic agents that may lead to more effective therapies for IDH-mutant glioma patients.
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Diffusion
Diffusion
Viral Mutations
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...

